BiotechTube

RVT-1401 680 mg/weekly + RVT-1401 340 mg/weekly

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Warm Autoimmune Hemolytic Anemia

Conditions

Warm Autoimmune Hemolytic Anemia

Trial Timeline

Aug 11, 2020 → Apr 1, 2021

NCT ID
NCT04253236

About RVT-1401 680 mg/weekly + RVT-1401 340 mg/weekly

RVT-1401 680 mg/weekly + RVT-1401 340 mg/weekly is a phase 2 stage product being developed by Immunovant for Warm Autoimmune Hemolytic Anemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT04253236. Target conditions include Warm Autoimmune Hemolytic Anemia.

What happened to similar drugs?

0 of 6 similar drugs in Warm Autoimmune Hemolytic Anemia were approved

Approved (0) Terminated (1) Active (5)
🔄Ianalumab + PlaceboNovartisPhase 3
🔄rituximab (Mabthera®) + PlaceboRochePhase 3
❌parsaclisinib + placeboIncytePhase 3
🔄Obexelimab + ObexelimabZenas BioPharmaPhase 3
🔄Fostamatinib disodiumRigel PharmaceuticalsPhase 3
🔄Fostamatinib disodium + PlaceboRigel PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04253236Phase 2Terminated

Competing Products

12 competing products in Warm Autoimmune Hemolytic Anemia

See all competitors
ProductCompanyStageHype Score
Ianalumab + PlaceboNovartisPhase 3
44
rituximab (Mabthera®) + PlaceboRochePhase 3
40
rilzabrutinibSanofiPhase 2
39
Isatuximab SAR650984SanofiPhase 2
27
parsaclisinib + placeboIncytePhase 3
29
HMPL-523(300mg PO QD) + PlaceboHUTCHMEDPhase 2/3
36
APL-2Apellis PharmaceuticalsPhase 2
29
Obexelimab + ObexelimabZenas BioPharmaPhase 3
38
ANX005AnnexonPhase 2
29
Fostamatinib 150 mg bidRigel PharmaceuticalsPhase 2
29
Fostamatinib disodiumRigel PharmaceuticalsPhase 3
41
Fostamatinib disodium + PlaceboRigel PharmaceuticalsPhase 3
34